Analyst Marcel Wijma of Van Leeuwenhoeck Institute has an updated Resverlogix research report available from July 24, 2018.

https://www.leeuwenhoeck.com/

"We have increased our valuation following very encouraging news from the FDA which encouraged us to lower the discount rate and increase the LOA for apabetalone in high risk diabetes and CKD patients. We also increased the number of potential patients by adding a Phase III subgroup of CVD patients with dementia/VCI. We believe that Resverlogix remains gravely undervalued at the current share price of CAD 2.34. We feel that the company’s current total value should be CAD 3.3 billion, or CAD 19.00 per share. This represents a substantial upside from the current share price."

August 2018 Resverlogix Fact Sheet is available on the Resverlogix Investor's page.